Highly porous large poly(lactic-co-glycolic acid) microspheres adsorbed with palmityl-acylated exendin-4 as a long-acting inhalation system for treating diabetes

Biomaterials

Volumn 32, Issue 6, 2011, Pages 1685-1693

  Kim, Hyunuk ^a   Park, Hongil ^a   Lee, Juho ^a   Kim, Tae Hyung ^b   Lee, Eun Seong ^c   Oh, Kyung Taek ^d   Lee, Kang Choon ^b   Youn, Yu Seok ^a  

^a Pusan National University   (South Korea)

^b Sungkyunkwan University   (South Korea)

^c The Catholic University of Korea   (South Korea)

^d Chung Ang University   (South Korea)

Author keywords

Albumin binding; Hydrophobic interaction; Inhalation; Palmityl acylated exendin 4; Porous microspheres; Pulmonary delivery

Indexed keywords

ALBUMIN-BINDING; HYDROPHOBIC INTERACTIONS; INHALATION; PALMITYL-ACYLATED EXENDIN-4; POROUS MICROSPHERES; PULMONARY DELIVERY;

ACYLATION; DRUG INTERACTIONS; DRUG PRODUCTS; MICROSPHERES; OPTIMIZATION;

HYDROPHOBICITY;

EXENDIN 4; MICROSPHERE; PALMITIC ACID DERIVATIVE; PALMITYL ACYLATED EXENDIN 4; POLOXAMER; POLYGLACTIN; POLYGLACTIN MICROSPHERE; SOLVENT; UNCLASSIFIED DRUG;

ACYLATION; ADSORPTION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; EMULSION; EVAPORATION; HISTOPATHOLOGY; HYDROPHOBICITY; INHALATION; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; POROSITY; PRIORITY JOURNAL; SUSTAINED DRUG RELEASE;

ADSORPTION; ANIMALS; DIABETES MELLITUS; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; HYPOGLYCEMIC AGENTS; LACTIC ACID; MALE; MICE; MICE, INBRED C57BL; MICROSPHERES; PEPTIDES; POLYGLYCOLIC ACID; POROSITY; VENOMS;

MUS;

EID: 78650264619     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.10.045     Document Type: Article

References (36)

1. Patton J.S., Fishburn C.S., Weers J.G. The lungs as a portal of entry for systemic drug delivery. Proc Am Thorac Soc 2004, 1:338-344.
2. Patton J.S., Byron P.R. Inhaling medicines: delivering drugs to the body through the lungs. Nat Rev Drug Discov 2007, 6:67-74.
3. Adjei A., Adjei A.L., Gupta P.K. Inhalation delivery of therapeutic peptides and proteins 1997, Marcel Dekker Inc, New York, 107-115.
4. Patton J.S. Mechanisms of macromolecular absorption by the lungs. Adv Drug Deliv Rev 1996, 19:3-36.
5. Youn Y.S., Lee K.C., Bae Y.H., Na K., Lee E.S. Advanced pulmonary delivery of peptides or proteins using polymeric particles. Delivery technologies for biopharmaceuticals: peptides, proteins, nucleic acids, and vaccines 2009, 228-244. WILEY. L. Jorgensen, H.M. Nielsen (Eds.).
6. Edwards D.A., Hanes J., Caponetti G., Hrkach J., Ben-Jebria A., Eskew M.L., et al. Large porous particles for pulmonary drug delivery. Science 1997, 276:1868-1871.
7. Edwards D.A., Ben-Jebria A., Langer R. Recent advances in pulmonary drug delivery using large, porous inhaled particles. J Appl Physiol 1998, 85:379-385.
8. Lee E.S., Kwon M.J., Lee H., Na K., Kim J.J. In vitro study of lysozyme in poly(lactide-co-glycolide) microspheres with sucrose acetate isobutyrate. Eur J Pharm Sci 2006, 29:435-441.
9. Kwon M.J., Bae J.H., Kim J.J., Na K., Lee E.S. Long acting porous microparticles for pulmonary drug delivery. Int J Pharm 2007, 333:5-9.
10. Lee E.S., Kwon M.J., Na K., Bae J.H. Protein release behavior from porous microparticle with lysozyme/hyaluronate ionic complex. Colloids Surf B 2007, 55:125-130.
11. Ungaro F., De Rosa G., Miro A., Quaglia F., Immacolata La Rotonda M. Cyclodextrins in the production of large porous particles: development of dry powders for the sustained release of insulin to the lungs. Eur J Pharm Sci 2006, 28:423-432.
12. Yang Y., Bajaj N., Xu P., Ohn K., Tsifansky M.D., Yeo Y. Development of highly porous large PLGA microparticles for pulmonary drug delivery. Biomaterials 2009, 30:1947-1953.
13. Sun L., Zhou S., Wang W., Li X., Wang J., Weng J. Preparation and characterization of porous biodegradable microspheres used for controlled protein delivery. Colloids and Surf A 2009, 345:173-181.
14. Chung H.J., Kim H.K., Yoon J.J., Park T.G. Heparin immobilized porous PLGA microspheres for angiogenic growth factor delivery. Pharm Res 2006, 23:1835-1841.
15. Kim H.K., Chung H.J., Park T.G. Biodegradable polymeric microspheres with "open/closed" pores for sustained release of human growth hormone. J Control Release 2006, 112:167-174.
16. Kim T.K., Yoon J.J., Lee D.S., Park T.G. Gas foamed open porous biodegradable polymeric microspheres. Biomaterials 2006, 27:152-159.
17. Davidson M.B., Bate G., Kirkpatrick P. Exenatide Nat Rev Drug Discov 2005, 4:713-714.
18. Xu G., Stoffers D.A., Habener J.F., Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999, 48:2270-2276.
19. Szayna M., Doyle M.E., Betkey J.A., Holloway H.W., Spencer R.G., Greig N.H., et al. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 2000, 141:1936-1941.
20. Edwards C.M., Stanley S.A., Davis R., Brynes A.E., Frost G.S., Seal L.J., et al. Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. Am J Physiol 2005, 81:155-161.
21. Chae S.Y., Jin C.H., Shin J.H., Son S., Kim T.H., Lee S., et al. Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs. J Control Release 2010, 142:206-213.
22. Son S., Chae S.Y., Kim C.W., Choi Y.G., Jung S.Y., Lee S., et al. Preparation and structural, biochemical, and pharmaceutical characterizations of bile acid-modified long-acting exendin-4 derivatives. J Med Chem 2009, 52:6889-6896.
23. Chae S.Y., Choi Y.G., Son S., Jung S.Y., Lee D.S., Lee K.C., et al. The fatty acid conjugated exendin-4 analogs for type 2 antidiabetic therapeutics. J Control Release 2010, 144:10-16.
24. Kim I., Kim T.H., Ma K., Lee E.S., Kim D., Oh K.T., et al. Synthesis and evaluation of human serum albumin-modified exendin-4 conjugate via heterobifunctional polyethylene glycol linkage with protracted hypoglycemic efficacy. Bioconjug Chem 2010, 21:1513-1519.
25. Morello M., Krone C.L., Dickerson S., Howerth E., Germishuizen W.A., Wong Y.-L., et al. Dry-powder pulmonary insufflation in the mouse for application to vaccine or drug studies. Tuberculosis 2009, 89:371-377.
26. Bivas-Benita M., Zwier R., Junginger H.E., Borchard G. Non-invasive pulmonary aerosol delivery in mice by the endotracheal route. Eur J Pharm Biopharm 2005, 61:214-218.
27. Lee K.C., Chae S.Y., Kim T.H., Lee S., Lee E.S., Youn Y.S., et al. Intrapulmonary potential of polyethylene glycol-modified glucagon-like peptide-1s as a type 2 anti-diabetic agent. Regul Pept 2009, 152:101-107.
28. Chae S.Y., Chun Y.G., Lee S., Jin C.H., Lee E.S., Lee K.C., et al. Pharmacokinetic and pharmacodynamic evaluation of site-specific PEGylated glucagon-like peptide-1 analogs as flexible postprandial-glucose controllers. J Pharm Sci 2009, 98:1556-1567.
29. Lee S.H., Lee S., Youn Y.S., Na D.H., Chae S.Y., Byun Y., et al. Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1. Bioconjug Chem 2005, 6:377-382.
30. Chuang V.T., Kragh-Hansen U., Otagiri M. Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm Res 2002, 19:569-577.
31. Markussen J., Havelund S., Kurtzhals P., Andersen A.S., Halstrøm J., Hasselager E., et al. Soluble, fatty acid acylated insulins bind to albumin and show protracted action in pigs. Diabetologia 1999, 39:281-288.
32. Kratz F. Albumin as a drug carrier: design of prodrugs, drug conjugates and nanoparticles. J Control Release 2008, 132:171-183.
33. Baker G.L., Gupta A., Clark M.L., Valenzuela B.R., Staska L.M., Harbo S.J., et al. Inhalation toxicity and lung toxicokinetics of C60 fullerene nanoparticles and microparticles. Toxicol Sci 2008, 101:122-131.
34. Huang Y.C., Vieira A., Huang K.L., Yeh M.K., Chiang C.H. Pulmonary inflammation caused by chitosan microparticles. J Biomed Mater Res A 2005, 75:283-287.
35. Fineberg S.E., Kawabata T., Finco-Kent D., Liu C., Krasner A. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. J Clin Endocrinol Metab 2005, 90:3287-3294.
36. Shive M.S., Anderson J.M. Biodegradation and biocompatibility of PLA and PLGA microspheres. Adv Drug Deliv Rev 1997, 28:5-24.